Modern methods that use systematic, quantitative and unbiased approaches are making it possible to discover proteins altered by a disease. To identify proteins that might be differentially expressed in autism, serum proteins from blood were subjected to trypsin digestion followed by liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) on time-of-flight (TOF) instruments to identify differentially expressed peptides. Children with autism 4-6 years of age (n = 69) were compared to typically developing children (n = 35) with similar age and gender distributions. A total of 6348 peptide components were quantified. Of these, five peptide components corresponding to four known proteins had an effect size > 0.99 with a P < 0.05 and a Mascot identification score of 30 or greater for autism compared to controls. The four proteins were: Apolipoprotein (apo) B-100, Complement Factor H Related Protein (FHR1), Complement C1q and Fibronectin 1 (FN1). In addition, apo B-100 and apo A-IV were higher in children with high compared to low functioning autism. Apos are involved in the transport of lipids, cholesterol and vitamin E. The complement system is involved in the lysis and removal of infectious organisms in blood, and may be involved in cellular apoptosis in brain. Despite limitations of the study, including the low fold changes and variable detection rates for the peptide components, the data support possible differences of circulating proteins in autism, and should help stimulate the continued search for causes and treatments of autism by examining peripheral blood.
Introduction
Autism is a heterogeneous neurodevelopmental disorder characterized by impairments in social interactions, deficits in verbal and non-verbal communication, and repetitive and stereotyped patterns of behavior. 1, 2 Although symptoms begin in infancy, diagnosis is dependent mainly on the recognition of the cardinal clinical signs that are present by 3 years of age. 3 Behavioral intervention is more effective the earlier it is initiated. [4] [5] [6] [7] Therefore, the identification of biological markers of autism would have a number of ramifications: markers could assist in the early and accurate diagnosis of the disorder; they may identify particular biological targets for treatment; and they could be used to define subgroups for specific treatments as well as for genetic studies.
So far, no biological or genetic markers for autism have been identified. Autism is a complex disorder that could have a number of 'causes'. It has a strong genetic component with the concordance rate in monozygotic twins (60% autism, 90% broader phenotype) being much higher than that of dizygotic twins (3%); and the sibling recurrence risk ratio being five to 10 times that for the general population. [8] [9] [10] Although previous linkage studies have identified a number of potential genetic loci for autism, only a few of these regions have been confirmed. [11] [12] [13] [14] [15] [16] [17] No single gene or group of genes have been unequivocally linked to autism, leading to suggestions that as many as 15 genes may weakly interact to confer a susceptibility to the disorder. 18, 19 Among the genes implicated in autism, several relate to immune regulation and function, including HLA-antigen presentation molecules and components of the complement system. 14, [20] [21] [22] [23] [24] [25] [26] [27] Although abnormalities of cytokines and chemokines have been reported in the blood of patients with autism including plasma levels of tumor necrosis factor-a (TNF)-a, TNF receptor II, Interferon-gamma (IFNg), Interleukin-12 (IL-12), and IL-10, no definitive profile has emerged. Indeed, the changes reported in cytokine levels may occur in separate subgroups of autism subjects that have different clinical phenotypes. [28] [29] [30] [31] [32] [33] [34] Other immune system alterations reported in subjects who have autism include the presence of autoantibodies in the blood directed to central nervous system (CNS) or brain antigens, and the presence of inflammation within the brain. [35] [36] [37] [38] Finally, an increased frequency of autoimmune disorders has been described in the families of individuals with autism. Comi et al. 39 found a positive correlation between the risk of autism and the number of family members affected with an autoimmune disease, with the highest risk associated with maternal autoimmunity. Similarly, immune disorders such as asthma and allergies, as well as the autoimmune diseases diabetes and psoriasis, were increased in mothers of children with autism spectrum disorder (ASD). 40 While these studies suggest that blood-borne molecules may be different in at least some phenotypes of autism, some studies had methodological problems or used small and heterogeneous samples of subjects. Moreover, relatively few molecules have been assayed. Thus, in order to more thoroughly examine potential markers, we have employed a proteomics approach with a relatively large and homogeneous population of children with autism. Proteomics uses a variety of different separation and mass spectrometry methods that enable the exploration of large numbers of serum proteins. Proteomics analysis has the advantage that it is relatively unbiased (except for its technical limitations), and does not make a priori assumptions about differences between sample groups. It is a powerful method that can generate new hypotheses by identifying candidate protein markers that may be important in disease pathogenesis and diagnosis. 41, 42 Proteomics approaches complement genetic and genome initiatives and may elucidate the protein products that are associated with genetic abnormalities involved in complex neurodevelopmental disorders such as autism. 43 Several recent studies have demonstrated the power of proteomics in understanding disease processes and elucidating the molecular defects associated with various conditions. 42, [44] [45] [46] [47] Junaid et al. 48 recently performed a proteomics study of autopsied brains of individuals with autism and found abnormalities that led to the identification of a single nucleotide polymorphism (SNP) in glyoxalase I, suggesting that it could be a susceptibility factor in autism. 48 The current cross-sectional study was designed to examine the proteome in serum from blood of children with autism (n = 69) ages four to six compared to typically developing children (n = 35) with similar age and gender distributions. Blood was drawn from children, the serum separated and subjected to column chromatography followed by mass spectrometry. The goal of this study was to identify a few of the most differentially expressed and most statistically significant peptides (and originating proteins) in the autism compared to control samples. A table of the data set will be included as a Supplementary Table.
Materials and methods

Study population
A total of 136 children between 4 and 6 years of age were enrolled in the study. Participants were recruited from the University of California at Davis MIND Institute Clinic and research database. Typically developing participants were recruited from area school districts and community centers.
The inclusion criteria for the autism group included a diagnosis of Autistic Disorder based on the DSM-IV criteria determined by an experienced neuropsychologist (BAC), which was further corroborated by the following measures. The Autism Diagnostic Observation Schedule-Generic (ADOS-G) 49 provides observation of a child's communication, reciprocal social interaction, and stereotyped behavior including an algorithm with cutoffs for autism and autism spectrum disorders. The Autism Diagnostic InterviewResearch (ADI-R) is a comprehensive, semi-structured parent interview that assesses a child's developmental history and relevant behaviors characteristic of autism and generates a diagnostic algorithm for Autistic Disorder. 50 Children who did not meet full autism criteria including pervasive developmental disorder-not otherwise specified (PDD-NOS) and Asperger Syndrome were excluded from the study. The Social Communication Questionnaire (SCQ) 51 was used as a screening tool to ensure the absence of symptoms of autism in the typically developing control children. One child who had scores above the cutoff (score = 15) was excluded from the typically developing group, and was referred for further diagnostic evaluation.
The Stanford-Binet Intelligence Scale 52 is a standardized measure of cognitive functioning administered to all participants to provide a measure of overall intellectual ability (IQ). The broad average range is defined by a mean of 100 and a s.d. of 16. The autism group was further divided based on full scale IQ as follows: High-functioning autism (HFA) having an IQ X68 and low-functioning autism (LFA) having an IQ < 68. Inclusion criteria for typically developing children (TYP) were: evidence of attaining normal developmental milestones; no diagnosis of autism or other developmental disabilities; and IQ X68.
A comprehensive medical history form, the AGRE Medical History Form (AGRE), was given to the parents of all participants to provide demographic, medical and family history information. Subjects were excluded from the investigation if they had a diagnosis of Fragile X or other serious neurological (e.g., seizures), psychiatric (e.g., bipolar disorder) or known medical conditions. All participants were screened via parental interview for current and past physical illness. Children with known endocrine, cardiovascular, pulmonary, liver, kidney or other medical disease were excluded from the study. Furthermore, failure to complete significant portions of the research protocol resulted in exclusion from the study. Twenty-two children were excluded due to failure to meet inclusion criteria, inability to balance across the group based on age or gender, or noncompliance with the protocol (e.g., unable to complete the blood draw). Further, the blood sample of one child with LFA was later determined to be unusable for proteomic analysis.
The final study group consisted of 104 children, 69 children with autism and 35 children in the typically developing group. Of the children with autism, 35 had HFA and 34 LFA. The children were chosen so that the age and gender distribution was similar in the three groups. The age range for the sample ranged from 4-years, 0-months to 6-years, 11-months. The gender ratio originally was the same across all three groups with 29 males and six females in each group. The loss of one sample due to missing Cysteine protection peaks in the MS data meant that the final composition of the LFA group was 29 males and five females. The HFA group had a mean age of 5.2 years and mean IQ of 79. The LFA group had a mean age of 5.5 years and a mean IQ of 55. The Typical group had a mean age of 5.7 years and an average IQ of 113. Descriptive statistics are presented in Table 1 .
At the time of the investigation, the following medications were being used by the participants (as reported by the parents): allergy/asthma medication (Albuterol, Claritin, Nasonex, solvent: TYP 3, HFA 
Sample collection procedures
Parents were asked to have their child fast prior to the blood draw, which required no consumption of food after midnight the evening before the collection. As part of the protocol, the family provided ongoing information regarding the health status of the child participant. The phlebotomy visit was rescheduled if the participant had been ill within the past 72 h or had an immunization within the past two weeks. The serum sample was collected in one 9.5 ml serum separator tube (BD Vacutainer SST tube, Becton Dickinson and Co; Franklin Lakes, NJ, USA). Samples were then sent chilled (on ice) to the proteomics lab (PPD, Menlo Park, CA, USA) and aliquots frozen within eight hours of blood draw. Lab personnel were blind to the diagnosis until after all samples were analyzed.
Mass spectrometry These methods have been described in previous publications from PPD. 41, [53] [54] [55] In brief, serum was fractioned into proteome and metabolome using a 5-kDa molecular weight cutoff spin filter (Millipore Corp., Bedford, MA, USA). Proteomic analysis was performed on serum proteins > 5000 Da. After dilution with 25 mM PBS buffer (pH 6.0), affinity beads (Prometic Biosciences, Cambridge, UK) were applied Identification of proteins was performed based upon the identification of peptides. Peptides of interest (significantly changing in expression level) were linked to tandem mass spectrometry (MS/MS) experiments on quadrupole TOF (Q-TOF) and iontrap mass spectrometers using extra or similar sample material. The resulting MS/MS spectra contain fragmentation patterns with characteristic peptide backbone cleavages. Each MS/MS raw spectrum from an isolated precursor ion is compared using commercially available software with in silico protein digestion and fragmentation using NCBI's RefSeq database to find a match, and hence identification. A matchquality score was reported based on Mascot software from Matrix Science for the identification of peptides. 58 
Quantification strategy
We used an approach developed by PPD for quantification of LC-MS data, applicable to large numbers of proteins/peptides and metabolites for the purpose of differential expression measurements and discovery of biomarkers for example. [54] [55] [56] [57] The differential quantification method used here relies on the changes in analyte signal intensities directly reflecting their concentrations in one sample relative to another. Samples are not mixed nor are the samples otherwise manipulated beyond that required for the LC-MS analysis itself. The sample preparation and LC-MS conditions need to be carefully controlled, however, for optimal results, and frequent quality control samples are analyzed to assure stable, reproducible performance.
This quantification technology employs overall spectral intensity normalization by employing signals of molecules that do not change concentration from sample to sample. In this way, a simple correction can be applied for any drift over time in overall LC-MS instrument response and/or differences in sample concentrations. PPD's proprietary MassView software performs normalization by determining the median of the ratios for a large number of molecular components, requiring no operator intervention. It also performs spectral smoothing, baseline subtraction, noise evaluation, isotopic analysis, peak identification, intensity evaluation, inter-scan evaluation to construct chromatographic peaks, inter-file (intersample) evaluation to establish molecular components for analysis, normalization (mentioned above), and quantification for the thousands of components (molecular ions corresponding to peptides).
Mass spectrometry data collection
Less than 1% of the samples were excluded from the statistical analyses because of technical difficulties. Specifically, data for one female LFA participant was invalid due to missing Cysteine protection peaks in the profile data (see patient data above).
Statistical methods
Statistical analyses were conducted to assess differences in proteomic variables. For the first comparison, all of the children with autism (HFA þ LFA; n = 69) were compared to the typically developing, normal controls (TYP, n = 35) using a univariate mean group (unpaired) comparison test that was either parametric (unpaired t-test) or non-parametric (Wilcoxon-Mann-Whitney test) depending on the normality of the data. Additional comparisons used paired tests with even numbers of subjects per group. Pairing was based on run order and matching by age and gender and was intended to reduce variability. Similar to the group analysis, the children with high functioning autism (HFA, n = 35) and low functioning autism (LFA, n = 34) were compared to each other and to typical children (TYP, n = 35) using either parametric (paired t-test) or non-parametric (paired Wilcoxon test) tests depending on the normality of the data. Goodness-of-fit statistics (Shapiro-Wilk) and tests of skewness and kurtosis were performed to assess normality. Each peptide component was assigned a univariate P-value. P < 0.05 were selected as differentially expressed. The effect size is the difference of the means of the two groups divided by the standard deviation that is weighted by the number of subjects in each group. The effect size (along with the P-value) was used to determine whether the peptides differentiated the groups. An effect size of 0.5 is modest, 1.0 strong and 2.0 very strong. The effect size provides an index of the absolute difference between groups as well as the variance. For the purpose of this study, we have listed the peptides with an effect size of 0.99 or greater in the tables. Fold change, on the other hand, is the average of intensities in diagnostic groups divided by the average of intensities in the typical group without taking variability within the groups into account (for unpaired tests) and is the average of the intensity ratios for paired comparisons. In addition, we only included peptides with Mascot scores greater than 30. 58 It is important to note that the greater number of peptides that identify a given protein, the more confident one is in the validity of the data. Finally, we included proteins that met the aforementioned criteria for which only one peptide was identified when other peptide components from the same protein gave consistent results, albeit with lower effect sizes or fold differences.
Results
Subjects
There were no statistical differences in ages among the three groups (TYP, HFA, LFA; F(2,101) = 0.065, P = 0.80). Table 1 shows the demographic information for the participants.
Proteomics A large number of the peptides were identified using the PPD peptide library coupled with additional directed tandem mass spectrometry. There were 6348 peptide components quantified at an occurrence threshold (detection rate) of 25%, meaning that the component had to be detected and quantifiable in at least 25% of the samples. Each component is a distinct molecular ion and is based on the peak observed isotope. Of the total peptide components tracked, 61% (3895) had a Mascot score of 15 or better and were identified with 576 known proteins (Tables  2 and 3 ), (i.e., NCBI RefSeq accession numbers). Of these known proteins, 48% had two or more identified peptides. Table 2 summarizes the findings for the comparison of children with autism to the typically developing children. Of the 6348 peptide components tracked, 243 were identified with a P < 0.05 (unpaired t-test) of which 151 were associated with known proteins. Similarly, Table 3 summarizes the findings for the comparison of the children with LFA compared to the children with HFA. In the comparison between LFA and HFA, of the 6348 peptide components tracked, 434 were identified with a P < 0.05 (paired t-test) of which 227 were known proteins. The data in both tables does not include any correction for multiple comparisons. When using multiple comparison correction (step-down Bonferroni P-value adjustment method of Holm 59, 60 no significant proteins were observed. As a result of this, we followed up on the identified proteins with some additional tests. Tables 2 and 3 also report the detection rate (DR) for the peptide components at each significance level. The DRs refers to the percentage of samples in which the peptide component could be detected. In samples that showed no value and were subsequently not available, it does not mean that the expression level was zero in the sample. Rather, the peptide could not be reliably detected in a given sample and beyond a given threshold. Generally, the DR did not differ among groups of subjects (medians HFA = 77, LFA, 71, TYP, 74). Differences in DR were < 40% for all components. Specific information can be found in the  Tables and Supplementary material. Because of the inability to find significant components utilizing multiple comparison corrections (i.e., Bonferroni-Holm, Benjamini-Hochberg), and the presence of missing values due to variable detection rate, this report focuses on the most expressed identified proteins with the highest effect size (0.99 or greater) and a P-value of < 0.05. Furthermore, for inclusion, the peptides needed to have a Mascot score of greater than 30. 58 The components without an ID are not included in the data or discussed here. All of the quantitative data in this study, however, including the components without an ID, will be provided in an Excel File to anyone interested in pursuing these results and will be supplied as supplemental tables to this report.
Autism (all children with autism) compared with typically developing children Using the above criteria, a total of five peptide components, that corresponded to four known proteins, were identified that were differentially expressed in serum of children with autism (n = 69) compared to typically developing children (n = 35) ( Table 4 ). Note that the figures presented below (Figures 1-4) show the differences across all three groups even though the findings pertain to statistical differences between autism (HFA and LFA combined) and typically developing children. Table 4 Apolipoprotein (apo) B-100 precursor was significantly lower in serum of the children with autism compared to the typically developing controls (Figure 1, Table 4 ). This protein was identified by ten peptide components (Table 4) . To further examine this relationship, we looked at the paired comparisons using the P < 0.05 selection criteria alone. Using these relaxed statistical criteria, for the HFA vs TYP comparison, 21 peptide components out of 229 were differentially expressed between HFA children compared to those with typical development (Table 5 ). The number that should have been significant by chance was (0.05)229 = 11.5, and the two-sided statistical significance of having a number as large as 21 is P = 0.0058. For the LFA vs TYP comparison, 37 peptides were differentially expressed (Table 6) , with P = 3.6 Â 10
À10
. Almost all of these peptides had a downward trend (21 of 21 in Table 5 ; 34 of 37 in Table  6 ) (the chance of 21 in 21 being down randomly is P = 9.5 Â 10 À7 (two-sided) and the chance of 34 in 37 being down randomly is P = 1.2 Â 10
À7
) and all had a Mascot score above 30 (except one in Table 5 ). These multiple peptides provide strong support for the differential expression of apo B-100 in autism (for both HFA and LFA).
A number of the differentially expressed proteins were related to the complement system (Figures 2-4 ; Table 4 ). Two of these proteins had only one peptide that met the full selection criteria (Table 4) . One peptide component showed the C Chain precursor of the C1q subcomponent to be upregulated in autism versus typical controls (Figure 2 ; Table 4 ). Two other components for C1q showed the same trend, but did not meet the P-value selection criteria. One peptide component showed that Fibronectin 1 isoform 1 (out of 20 detected for this protein) was upregulated in autism versus typical controls ( Figure 3 ; Table 4 ). For the other components for Fibronectin 1 isoform 1, however, 18 of 19 showed the same upward trend, but did not meet the P-value selection criteria. This result has a two-sided binomial P-value of P = 0.000040.
Two different peptide components (out of three detected for this protein) met the criteria (effect size > 0.99; P < 0.05) for showing upregulation of Complement factor-H-related protein 1 precursor (FHR-1) in autism compared to typically developing children (Table 4 ). Figure 4 , which uses one of the two different peptides from the FHR-1 protein, shows higher expression of FHR-1 in both the HFA and LFA subgroups compared to the typically developing children. It is important to emphasize that a number of other peptides were also detected related to the complement system (P < 0.05), but are not shown in the Figures or Tables because they did not have an effect size of > 0.99. These included peptides corresponding to FHR1, Fibronectin, complement component 4B proprotein and complement 3 precursor protein, and other complement proteins that are included in the Supplementary Tables to this report. These proteins were significantly different in autism (n = 69) compared to typical children (n = 35) (Pp0.05, unpaired t-test) and had an effect size of 0.99 or greater. Down (À) indicates lower levels in serum of children with autism compared to typical children. Peptide detection rate (DR) percentages are presented for all three groups.
Additional evidence that the differences in the complement proteins are real rather than statistical artifacts comes from the fact that three of the four proteins chosen according to the stringent criteria used for this study are from the complement system, suggesting a non-random concurrence.
Low functioning autism vs high functioning autism
Apo B-100 and apo A-IV were lower in the serum of the children with LFA compared with the children with HFA (Table 7) . Apo B-100 was identified by nine peptides and Apo A-IV was identified by six peptides (Table 7 ; effect size > 0.99 and P < 0.05). As noted above, Apo B-100 is also decreased and on the list of proteins that differentiate all children with autism from typically developing children (Table 4) . A number of peptides related to the complement family were also differentially expressed in LFA vs HFA but did not meet the criteria to be included in Table 5 . Details regarding these peptides are available as a supplement to this report. These peptides are Figure 1 Apo B-100 (SEILAHWSPAK) concentrations in children with low functioning autism (LFA ) and high functioning autism (HFA ) compared to typical developing, normal children (typical . The peptide sequence used to identify this protein, the Accession Number, P-value and effect size are given in . The peptide sequence used to identify this protein, the Accession Number, P-value and effect size are given in Complement factor H (TGESAEFVCK) concentrations in children with low functioning autism (LFA ) and high functioning autism (HFA ) compared to typical developing, normal children (typical ). The peptide sequence used to identify this protein, the Accession number, P-value and the effect size are given in Table 4 . The medians for the normalized peak areas for the three groups are: LFA 51.19, HFA 49.81, TYP 35.01; and the interquartile ranges are 8.8, 18.32 and 12.18, respectively. These findings were comparable to the other peptide ITC-TEEGWSPTPK that also identified FHR-1 (see Table 4 ). These peptides were significantly different between HFA (n = 35) compared to typical children (n = 35) (P < 0.05, paired t-test). Effect size was not considered for selection of these components. Shading indicates levels of significance: darkest grey = P < 0.001, dark grey = P < 0.005, light grey = P < 0.01, white = P < 0.05.
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related to the following known proteins: complement C1r component precursor, complement component C9 precursor, complement component C8 beta chain precursor, clusterin isoform 1 or complement-associated protein SP-40, complement factor I precursor (C3B/C4B inactivator), Fibronectin precursor, and nuclear receptor co-activator 4 (NCoA-4) (70 kDa androgen receptor co-activator).
Discussion
The results support many previous studies that demonstrate differences of circulating immune related proteins in individuals with autism. 28, 34 The current proteomic study has identified a number of circulating proteins that appear to be abnormal in autism compared with controls. Five peptide components showed the biggest differences between the Autism and the Typical groups, four of which correspond to three proteins involved in the complement pathway. Our data suggests peripheral differences of immune molecules including complement that could impact indirectly on the developing brain in autism. Alternatively, the same or similar molecules within the brain might be abnormal and contribute directly to abnormal brain development and autism.
Apolipoproteins
Apo are involved in the transport of lipids, cholesterol and vitamin E in the circulation and play a general role in the maintenance of lipid homeostasis. Apo B is a key structural component of several lipoproteins and is present in two forms: apo B (ApoB100) and These peptides were significantly different between LFA (n = 34) compared to typical children (n = 35) (Pp0.05, paired t-test). Effect size was not considered for selection of these components. Shading indicates levels of significance: darkest grey = P < 0.001, dark grey = P < 0.005, light grey = P < 0.01, white = P < 0.05.
ApoB48. ApoB100 is present on very low-density lipoproteins (VLDL), intermediate density lipoproteins (IDL) and LDL. ApoB100 assembles VLDL particles in the liver that starts formation of a pre-VLDL, which is retained in the cell unless converted to the triglyceride-poor VLDL2. Owing to its role in lipid transport and cholesterol homeostasis, it is not surprising that increased levels of ApoB100 plays a central role in the increased risk of vascular disease and the development of atherosclerosis. 61 Additionally, it has been reported that visceral obesity can lead to overproduction of ApoB100. 62 The current data indicate a reduction in most peptide components for apo B-100, which differentiated the autism group as a whole from typical children as well as differentiating between LFA and HFA children. It is notable that overlapping as well as different peptides from the apo B-100 protein are lower in children with autism compared to controls (Table 4) , HFA vs controls (Table 5) , LFA versus controls (Table 6 ) and HFA vs LFA (Table 7) . To complicate this even further, three of the 37 peptides regulated in the LFA vs Typical controls comparison show upregulation (Table 6 ). Though the explanation for these findings could be due to technical issues with proteomics, they could also relate to complex proteolytic cleavage of the whole apo B-100 protein.
The data might suggest that apo B-100 protein is cleaved differently in HFA and LFA autism compared to controls, and perhaps some of the cleaved products of Apo B-100 proteins are differentially regulated so that most go down in autism but a few peptide components go up. Future studies will be required to sort out the explanation for these findings. The finding of increased apo E mRNA in the brains of subjects with autism 63 also shows up regulation of a different lipoprotein in autism.
It is unclear what the significance of the decrease in the apo is in the serum of the children with autism. It is possible that this indicates some abnormality of the gastrointestinal system, perhaps related to the immune abnormalities reported in the gastrointestinal tract in children with autism, that affects the apo. 29, 31, 64, 65, 66 Alternatively, the changes in apo could be due to differences in diet or various treatments.
Another possibility relates to the influence of the hypothalamic-pituitary-adrenocortical (HPA) system on lipid metabolism. Adrenocorticotropic hormone (ACTH) is a major component of the HPA axis and is involved in the regulation of lipid metabolism. 67 Children with autism demonstrate dysregulation of the HPA and are over-responsive to stress as shown by increases in cortisol. 68 ACTH directly and selectively decreases the expression and secretion of apo B in vitro, 69 hence possibly providing a link between stress and changes of ApoB-100.
As noted, two different apo were increased in the serum of children with HFA compared to LFA. Apo A-IV is a plasma lipoprotein synthesized mainly in small intestine enterocytes during fat absorption. 70 It regulates lipid absorption, transport and metabolism 70 and may also act as a satiety signal. 71 The finding that apo, especially ApoB 100, are reduced in children with autism warrants additional study to determine if it may play a role in CNS pathology, gastrointestinal function or even secondary factors, such as stress. As noted above, ApoE lipoprotein mRNA is elevated in the brain of individuals with autism, 63 perhaps suggesting a more generalized dysregulation of apometabolism in autism.
The complement system Four of the seven major peptide components identified in this study correspond to proteins that are involved in the complement system, including increases in the C Chain precursor protein for complement factor-H related protein 1 precursor, complement C1q subcomponent, and fibronectin 1 isoform 1 preprotein. All of these proteins play a role in the complement system cascade, and are involved in complement activation pathways. [72] [73] [74] As part of the innate immune system, the complement system acts as one of the first lines of defense for the lysis and removal of invading microbes. In addition, the complement system modulates the activation of B-lymphocytes and the production of antibodies, promotes chemotaxis and phagocyte recruitment, and is involved in the transport and clearance of immune complexes while preserving normal cells. Over 30 serum glycoprotein members of complement are activated in a tightly controlled, sequenced cascade. There are three main pathways that activate complement in response to an infection or foreign antigen: (1) the classical pathway -IgG and IgM driven antigen-antibody reactions; (2) the alternative pathway that is activated by polysaccharides from yeast, Gram-negative bacteria and other organisms and is independent of antibodies; and, (3) the lectin pathway (mannan-binding lectin -MBL pathway) that is activated when stimulated by mannose containing proteins found in viruses, yeasts and other organisms and is similar to the classical pathways but does not involve antibodies. 72 All three pathways activate the central C3 component.
Complement protein C1q and the classical pathway
C1q protein appears to be increased in serum of children with autism. C1q is intimately involved in the classical pathway of complement activation. C1q, the recognition subcomponent participates in the initial steps of the activation of the classic pathway and is involved in the MBL pathway. 74 Phagocytosis of cellular targets, such as invading microbes and apoptotic cells, is enhanced if coated (opsonized) with complement including C1q. 75, 76 Interestingly, increased deposition of C1q has been described in a group of autism patients with gastrointestinal symptoms, in which enhanced deposition of C1q was detected on intestinal epithelial cells and was co-localized with IgG. 77 This finding suggests that a C1q-antibody driven lytic response directed against a potential self-antigen in the intestinal cells, which could perturb the barrier functioning of the intestine, may be important in this subgroup of patients with autism. C1q not only plays a role in identifying cells for lysis, but also plays a role in the recruitment of inflammatory cells. 78, 79 C1q knockout mice have a profound impairment of clearance of apoptotic cells. 80 This may be important in autism as neurons are notably sensitive to complement and specifically C1q mediated cell death. 81 Fibronectin 1. Fibronectin proteins are also involved in the classical pathway and appear to be increased in serum of children with autism. Fibronectin 1 isoform (FN1, LETS) is a multifunctional extracellular matrix glycoprotein that participates in cell migration, signaling to adhering cells, apoptosis and in the complement system. Fibronectins bind a large number of molecules including fibrin, complement, collagen, heparin, proteoglycans and cells and bacteria. 82 One of the functions of fibronectin-1 is adhesion of cells to extracellular materials. Specifically, fibronectin binds to C1q and is involved in the clearance of C1q coated material like immune complexes, infectious agents and cellular debris. 82 Factor H-related protein. Complement Factor Hrelated protein (FHR-1) appears to be increased in the serum of children with autism. Although the function of FHR-1 is not known, it is part of the multidomain, multifunctional Factor H gene family. Factor H is a plasma protein that plays an essential role in inhibiting complement activation in fluid phase and on cellular surfaces. 83 Factor H inhibits complement activation partly by inhibiting the BF-C3 complex in the alternate complement activation pathway. In addition, Factor H acts as an extracellular matrix component that binds to integrin receptors and interacts with various ligands. 84 FHR-1, the Factor H-like protein upregulated in the serum of children with autism in this study, is likely to have similar functions.
The factors that might produce these changes of complement are uncertain since upregulation of C1q and Fibronectin would activate complement, and the up regulation of FHR1 would inhibit complement. It is possible that one or more of these changes is due to genetic effects. For example, Odell et al.
14 evaluated 85 families with a child with autism compared to 69 control families. Nearly half (42.4%) of the subjects carried at least one C4BQ0 allele as compared with 14.5% of the controls (P = 0.00013, relative risk 4.33). More than half of the C4B null alleles in subjects with autism involved C4A duplications. 14 It is possible that a modest genetic abnormality of C4B might affect other complement proteins including fibronectin, C1q and FHR-1.
Should these changes of complement proteins be confirmed in future studies, it is unclear how differences of various components of complement might contribute to autism. It is possible that the complement changes predispose to viral or other infections of mother or fetus during development, or to abnormal autoimmune responses, and that the ensuing immune response causes abnormalities of brain development that result in autism. Alternatively, it is possible that complement within the brain is abnormal and this directly contributes to abnormalities during neurodevelopment.
Role of complement in the brain
Complement plays a direct role within the nervous system, and is probably involved in cell death and apoptosis of cells during normal development and in CNS diseases like Alzheimer's, Huntington's disease, stroke and many others. 81, 85 Most of the complement proteins found in blood are also expressed in the brain, mainly by microglia and to a lesser extent by stressed or damaged astrocytes and neurons. 81, 86, 87 C1q, C3, C4, C5, C6, C9, CR1, C1qRp, CR3, CR4, Factor H and others have been shown to be upregulated in brain in humans and experimental animals with infection, ischemia and stroke, Alzheimer's disease, prion disease, Huntington's chorea and many other CNS diseases. 81, 85, 86 C1q-deficient mice have less injury following cerebral ischemia and have less neuropathology in transgenic mouse models of Alzheimer's disease. 88, 89 Factor H is found in brain and may contribute to intracerebral complement system. 90 Fibronectin-deficient mice show increased neuronal apoptosis in brain. 91 Reelin (RELN) is an extracellular matrix protein that plays a pivotal role in the development of the CNS 92 and has been considered a candidate gene in autism. 10 Reelin, which must be secreted into the extracellular matrix to exert its biological effect, 93 degrades fibronectin 94 and hence could regulate fibronectin-C1q related removal of apoptotic cells in the nervous system.
With the alteration of complement proteins in serum of subjects with autism in this study, it is interesting to note a recent report of evidence of inflammation in the brains of individuals with autism. 38 Vargas et al. 38 found evidence of microglial activation in the cortex, subcortical white matter and the cerebellum of patients with autism consistent with a chronic and sustained neuroglial inflammatory response. It was suggested that activation of microglia could trigger complement activation that would contribute to brain injury. 38 
Limitations
Although the proteomic approach appears promising in the discovery of putative biological markers, the data also highlight the major difficulties facing previous and future studies. The small fold changes observed could indicate that there are specific subgroups that account for the changes detected in the group as a whole; or that the changes that occur in the serum are indeed small and that future replication will require quantitative and well-controlled studies.
A major challenge in proteomics pertains to the criteria used in the identification of proteins. 42 As there is a degree of uncertainty in the selection of peptides, we provided the Mascot score to provide some measure of confidence. 58 Thus, there is the concern of limited reproducibility and the need to unify and standardize the analytical methods. 47, 95 Many or most monitored proteins are unanticipated at the time of study, eliminating the possibility of prior relative sensitivity factors. Additionally, methods based on introducing a known amount of a chemically analogous extraneous substance as an internal standard (i.e. 'spiking' of a standard reference material) are not practical.
In our results we include proteins for which only one peptide met the selection criteria when it was biologically related in a meaningful way to a protein with more than one peptide. However, we acknowledge that the greater number of peptides that identify a given protein the more confident one is in the validity of the data. The detection rate in some of the samples, such as C1q, is quite low and may simply represent a subpopulation of children with autism or extreme outliers. Further, proteins such as apo B-100 are highly abundant and the biological significance of small fold changes is unknown. Therefore, the data must be interpreted with caution. It will be important for future studies to include confirmatory analyses with alternative methods to support such findings.
Further, our analytic approach was based predominantly on statistical significance and selecting the proteins with the largest effect size for further analysis. The identification of other important proteins and peptides may show less statistical relevance, but ultimately reveal more biological importance in the study of autism. As autism is a heterogeneous disorder and these methods do not identify absolute values in the sample, future studies are clearly warranted to confirm and elucidate these findings.
Finally, since we are measuring peripheral blood, some of the abnormalities observed in the autism group may be due to a secondary factor, such as the individual's response to stress (venipuncture). Some children with autism respond to novel environmental stimuli by marked increases in salivary cortisol 68 that can also be detected in blood. It will be important for future studies to consider alternative explanations such as these when inferring CNS changes based on peripheral samples.
In summary, the proteomic approach used in this investigation succeeded in identifying a number of differentially expressed peptides that correspond to known proteins including apos and several involved in the complement cascade. This study demonstrates the potential of the proteomics approach, provides encouraging initial data, and should help stimulate the continued search for the causes and novel treatments of autism by examining peripheral blood.
